Accenture has invested in Ryght AI to support the use of agentic AI in modernising clinical research for the life sciences industry. The investment, made through Accenture Ventures, is aimed at helping life sciences and clinical research companies accelerate the development of new treatments by improving how clinical trials are designed and executed.
Clinical trials are growing increasingly complex, with delays often arising during site selection and patient enrolment. Manual processes can add weeks or months to study timelines, driving up costs and slowing the introduction of new therapies.
Ryght AI addresses these challenges through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites using historical performance data, patient demographics and real-time operational information. This enables sponsors and contract research organisations to identify suitable sites more efficiently, improve enrolment forecasting and streamline site activation while meeting regulatory and protocol requirements.
The collaboration combines Accenture’s industry, technology and data-engineering expertise with Ryght AI’s domain-specific agentic AI platform to accelerate key stages of drug development, including trial feasibility, site selection and patient recruitment. Financial terms of the investment were not disclosed.
The move marks Accenture’s latest investment in technology-driven biotechnology companies focused on accelerating clinical trials and drug discovery, following earlier backing of firms such as 1910 Genetics, Turbine and Earli.
